Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 1/20 | 0.33 |
| ▸ | P2RY6 | Q15077 | 10/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.33 |
| ▸ | UMPS | P11172 | 1/20 | 0.33 |
| ▸ | EIF4E | P06730 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18290449 | 1.00 | DNPH1 (0.33) | DNPH1P2RY6P2RY14UMPSEIF4E | |
| SCHEMBL14930934 | 0.94 | DNPH1 (0.34) | DNPH1P2RY6P2RY14UMPSEIF4E | |
| SCHEMBL18844822 | 0.93 | P2RY6 (0.34) | DNPH1P2RY6P2RY14UMPSEIF4E | |
| SCHEMBL15870442 | 0.93 | P2RY6 (0.34) | DNPH1P2RY6P2RY14UMPSEIF4E | |
| SCHEMBL15250721 | 0.93 | P2RY6 (0.34) | DNPH1P2RY6P2RY14UMPSEIF4E | |
| SCHEMBL15259295 | 0.93 | P2RY6 (0.34) | DNPH1P2RY6P2RY14UMPSEIF4E | |
| SCHEMBL15047317 | 0.88 | P2RY6 (0.35) | DNPH1P2RY6P2RY14UMPSEIF4E | |
| SCHEMBL17814764 | 0.87 | DNPH1 (0.33) | DNPH1P2RY6P2RY14UMPSEIF4E | |
| SCHEMBL15764141 | 0.87 | DNPH1 (0.33) | DNPH1P2RY6P2RY14UMPSEIF4E | |
| SCHEMBL16597025 | 0.87 | DNPH1 (0.33) | DNPH1P2RY6P2RY14UMPSEIF4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160289674-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS | MODERNATX, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160256573-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | MODERNATX, INC. | 2016-09-08 | — | — | US | disclosed |
| US-8664194-B2 | Method for producing a protein of interest in a primate | MODERNA THERAPEUTICS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130237592-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST AT THE SITE OF A CLOT | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | DNPH1 467/4885P2RY6 339/4885P2RY14 531/4885 |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | DNPH1 1736/4885P2RY6 1545/4885P2RY14 2361/4885 |
| US-20160256573-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | RNMT, NSUN2, NSUN3 | DNPH1 1585/4885P2RY6 1139/4885P2RY14 2299/4885 |
| US-20160289674-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS | POLRMT, POLN, MSH2 | DNPH1 3518/4885P2RY6 1367/4885P2RY14 1731/4885 |
| US-20130237592-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST AT THE SITE OF A CLOT | TIA1, PAIP1, PHAX | DNPH1 3239/4885P2RY6 3631/4885P2RY14 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.